English 
搜索
Hebei Lansheng Biotech Co., Ltd. ShangHai Yuelian Biotech Co., Ltd.

United Kingdom - Proposal to withdraw approval of the active substance indoxacarbqrcode

Sep. 5, 2022

Favorites Print
Forward
Sep. 5, 2022

The Health and Safety Executive (HSE) has conducted a review of the approval of the active substance indoxacarb and proposes to withdraw the approval.

HSE reviewed the approval of indoxacarb in light of new scientific information which indicated that the active substance may no longer satisfy the criteria for approval.

The review considered the effect on the risk assessment of new toxicological reference values for this active substance, alongside comments provided by producers and authorisation holders.

In particular, it was found that non-dietary exposure for various representative uses was above acceptable limits for operators, workers, residents, and bystanders. HSE therefore proposes to withdraw approval of indoxacarb in Great Britain (GB).

Details of this proposal will now be forwarded to the World Trade Organisation for consultation with trading partners.

Further information and developments relating to the approval of indoxacarb will be recorded in the statutory approvals register of active substances.


Source: hse.gov.uk

0/1200

More from AgroNewsChange

Hot Topic More

Subscribe Comment

Subscribe 

Subscribe Email: *
Name:
Mobile Number:  

Comment  

0/1200

 

NEWSLETTER

Subscribe AgroNews Daily Alert to send news related to your mailbox